Sign up for the QMED & MD+DI Daily newsletter.
2013 Medtech M&A Review: Biggest Deal of the Year—Thermo Fisher Scientific Acquires Life Technologies
The blockbuster transaction in 2013 was life science research product giant Thermo Fisher Scientific’s acquisition of Life Technologies Corp., a leading producer of biotech and genetic testing equipment, for $13.6 billion. The deal was Thermo Fisher largest transaction since its formation in 2006 through the $12.8 billion merger of Thermo Electron and Fisher Scientific.
November 15, 2013
1 Min Read
.svg?width=1280&auto=webp&quality=95&format=jpg&disable=upscale "MDDI")
The deal gives Thermo Fisher a major position in the genetic sequencing market.
By Clyde A. Burkhardt.
The acquisition gives Thermo Fisher, which has focused on research and diagnostic products, a major position in the genetic sequencing market, which is projected to grow to $6.6 billion by 2016. The biggest player in gene sequencing is currently Illumina, which Roche made an unsuccessful bid to buy last year. Illumina is likely to see another offer from Roche or another major medtech company in the future.
Clyde A. Burkhardt is senior managing director of HT Capital Advisors LLC (New York City), a private investment banking firm. He leads HT Capital Advisors' groups focusing on the medical device, healthcare services, and precision component industries. Contact Burkhardt at [email protected].
You May Also Like
.svg?width=700&auto=webp&quality=80&disable=upscale)
.png?width=700&auto=webp&quality=80&disable=upscale)
